Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : says COVID-19 vaccine trial in U.S still on hold

share with twitter share with LinkedIn share with facebook
09/19/2020 | 10:38pm EDT
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

AstraZeneca Plc said on Saturday that its COVID-19 vaccine trial in the United States is still on hold.

AstraZeneca on Saturday published a document https://bit.ly/2FNcqu7 describing details of how the COVID-19 vaccine trial was being carried out, which was first reported by the New York Times.

(Reporting by Rama Venkat in Bengaluru; Editing by Michael Perry)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.53% 8091 Delayed Quote.6.03%
THE NEW YORK TIMES COMPANY -1.21% 43.28 Delayed Quote.34.54%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:58aGSK to launch late-stage testing of syncytial virus vaccine
RE
10/20Australian shares gain on renewed U.S. stimulus hopes
RE
10/20EXCLUSIVE : U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - so..
RE
10/20EXCLUSIVE : U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - so..
RE
10/20Mexico could share some COVID-19 vaccine liabilities with laboratories
RE
10/20China's Sinovac vaccine to be included in Brazil's immunization program, gove..
RE
10/20China's Sinovac vaccine to be included in Brazil's immunization program, gove..
RE
10/20Mexico could absorb some COVID-19 vaccine liabilities
RE
10/20ASTRAZENECA : Tagrisso granted Priority Review in the US for the adjuvant treatm..
AQ
10/20ASTRAZENECA : Granted US Priority Review for Early-Stage Lung Cancer Adjuvant Dr..
DJ
More news
Financials (USD)
Sales 2020 26 717 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 172 M - -
P/E ratio 2020 47,8x
Yield 2020 2,70%
Capitalization 137 B 137 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,91x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,15 $
Last Close Price 104,50 $
Spread / Highest target 48,8%
Spread / Average Target 13,1%
Spread / Lowest Target -36,8%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.03%137 175
JOHNSON & JOHNSON-0.90%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-3.52%210 050
MERCK & CO., INC.-13.94%198 975
NOVARTIS AG-14.48%190 349